check quantity

AlphaLISA SureFire Ultra p-ERK1/2 (Thr202/Tyr204) Assay Kit - 10,000 Assay Points

AlphaLISA SureFire Ultra Phospho-protein

false

The AlphaLISA^® SureFire^® Ultra^™ p-ERK 1/2 (Thr202/Tyr204) assay is a sandwich immunoassay for quantitative detection of phospho-ERK 1/2 (phosphorylated on Thr202/Tyr204 in ERK1, or Thr185/Tyr187 in ERK2) in cellular lysates using Alpha Technology.

true false

ALSU-PERK-A-HV

100 Assay Points

553.00 USD

ALSU-PERK-A500

500 Assay Points

1868.00 USD

ALSU-PERK-A10K

10,000 Assay Points

11400.00 USD

ALSU-PERK-A50K

50,000 Assay Points

35300.00 USD

Buy Now

Please enter valid quantity

Please log in to add favorites.

NULL OR EMPTY CART

Overview
Resources, Events & More
Tools

Overview

Formats:

The HV (high volume) kit contains reagents to run 100 wells in 96-well format, using a 60 µL reaction volume.
The 500-point kit contains enough reagents to run 500 wells in 384-well format, using a 20 µL reaction volume.
The 10,000-point kit contains enough reagents to run 10,000 wells in 384-well format, using a 20 µL reaction volume.
The 50,000-point kit contains enough reagents to run 50,000 wells in 384-well format, using a 20 µL reaction volume.

In the AlphaLISA^® SureFire^® Ultra^™ assay, Donor beads are coated with streptavidin to capture one of the antibodies, which is biotinylated. Acceptor beads are coated with a proprietary CaptSure^™ agent that immobilizes the other antibody, labeled with a CaptSure^™ tag. In the presence of phosphorylated protein, the two antibodies bring the Donor and Acceptor beads close together, generating signal. The amount of light emission is directly proportional to the amount of phosphoprotein present in the sample.

AlphaLISA^® SureFire^® Ultra^™ kits are compatible with:

Cell and tissue lysates
Antibody modulators
Biotherapeutic antibodies

Alpha SureFire^® kits can be used for:

Cellular kinase assays
Receptor activation studies
Screening

Specifications

Assay Pathway	MAPK
Assay Target	ERK1/2
Assay Target Class	Phosphoprotein
Automation Compatible	Yes
Detection Method	Alpha
Product Brand Name	AlphaLISA SureFire Ultra
Quantity in a Package Amount	10000.0 Units
Shipping Condition	Blue Ice
Therapeutic Area	Central Nervous System, Cardiovascular, Neuroinflammation
Unit Size	10,000 Assay Points

Resources, Events & More

Application Brief

Eight Limitations of ELISA and How to Overcome Them Using Alternative Technologies

The introduction of enzyme-linked immunosorbent assays (ELISAs) in the early 1970’s offered researchers a non-radiometric immunoassay platform without compromising sensitivity. Over the last 50 years scientists have made huge strides in disease research and drug discovery and a demand for greater assay throughput and sensitivity has evolved. In response, more robust immunoassays have been developed to address some of the limitations of the standard, colorimetric ELISA.

Find out about the most common limitations of traditional ELISAs and how different ELISA alternative technologies address these limitations.

PDF 1 MB

Application Note

Characterizing Chemokine Receptor Inhibitors with AlphaLISA SureFire Ultra

PDF 2 MB

Effects of 5FU and Sorafenib on Proliferation and Biomarker Expression in a Colorectal Cancer Model Using AlphaLISA and EnSight Solutions

A variety of chemotherapeutic drugs with different modes of action have been developed and tested as potential therapies for colorectal cancer. Characterizing the effects of potential drugs with different modes of action is a key part of the process.

In this application note you will learn:

How to rapidly measure multiple biomarkers in both cell culture supernatant and lysates from the same wells of a microplate to examine complex protein expression profiles from a colorectal cancer cellular model
Benefits of using AlphaLISA^® technology for characterizing the effects of potential drugs with different modes of action on a cell culture model of human colorectal cancer
How to measure the effects of drug treatments, such as 5FU and Sorafenib, on cellular proliferation by automated well-imaging and cell counting using the EnSight^® multimode plate reader
Examples of the data and analysis you can generate for such biomarker and proliferation assays

PDF 3 MB

Multi-Parametric Assessment of EGF Treatment Effects on Signaling Pathways, Growth and Proliferation Using AlphaLISA SureFire Ultra and Cellular Imaging

In this application note, we demonstrate an efficient cell-based workflow for the assessment of EGF treatment effects in a cellular model of human skin cancer.

Treatment effects on several intracellular signaling pathways were examined using PerkinElmer’s homogeneous, no-wash AlphaLISA^® SureFire^® Ultra assays. To determine concurrent time-dependent effects of different EGF concentrations on cellular health and proliferation, ATP concentrations were assessed with ATPlite™ 1step luminescence assay and cultures were fluorescently labeled, imaged and analyzed using the Operetta CLS™ high-content analysis system.

PDF 6 MB